Analystreport

Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.

Regulus Therapeutics Inc.  (RGLS) 
Last regulus therapeutics inc. earnings: 3/12 04:37 pm Check Earnings Report
US:NASDAQ Investor Relations: regulusrx.com/investors